Novo Nordisk (NVO)
(Delayed Data from NYSE)
$126.88 USD
+0.03 (0.02%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $127.49 +0.61 (0.48%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NVO 126.88 +0.03(0.02%)
Will NVO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NVO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVO
Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?
Beat the Market the Zacks Way: ADMA Biologics, Carlisle, McCormick Manufacturing in Focus
NVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why
4 Large Drug Stocks to Hold on to Amid Industry Challenges
Other News for NVO
Uranium, Battery, and Precious Metals Virtual Investor Conference Agenda Announced for April 30th - May 2nd
Novo Nordisk: Growth Is Still A Better Choice
Decoding Novo Nordisk's Options Activity: What's the Big Picture?
Artisan International Explorer Fund Q1 2024 Commentary
What do weight-loss drugs mean for the diet industry?